Effects of memantine on the excitation-inhibition balance in prefrontal cortex
Introduction
Alzheimer's disease (AD) is a devastating brain disorder that heavily burdens the aging American population. Although a daunting challenge, creating new AD therapeutics can be aided by better understanding of the mechanisms of action of existing AD drugs.
Memantine has been used to treat AD and other dementias for more than two decades. Although memantine binds to a number of receptors, it is generally believed that the therapeutic effects of memantine are mainly associated with N-methyl-d-aspartate receptor (NMDAR) channel block (Lipton, 2006, Parsons et al., 2007, Johnson et al., 2015). There is no general agreement on how NMDAR channel block by memantine slows cognitive decline in AD patients. Several mechanisms of memantine action have been proposed, the majority of which are based on memantine's neuroprotective action. The neuroprotective effect of memantine could result from prevention of excitotoxicity due to excessive NMDAR excitation in pathological brain conditions (Lipton, 2006), or from preferential inhibition of extrasynaptic NMDARs (Leveille et al., 2008, Xia et al., 2010) based on the hypothesis that extrasynaptic NMDAR activation can lead to cell death (Hardingham and Bading, 2010) (but see (Wroge et al., 2012)). However, there is evidence arguing against therapeutic effects of memantine based solely on neuroprotection, e.g. the lack of beneficial effects in early-stage AD, and the rapidity of memantine's effects (Johnson and Kotermanski, 2006).
The ability of memantine to slow cognitive decline in AD patients has also been proposed to result from partial correction of an AD-induced alteration of cortical excitation/inhibition (E/I) balance (Schmitt, 2005). A delicate balance of excitatory and inhibitory elements in the cortex is essential to circuit function, and disturbances of this balance can lead to pathological conditions (Homayoun and Moghaddam, 2007, Haider and McCormick, 2009). There is strong evidence that the E/I balance is shifted away from excitation in AD. A decrease in cortical activity (Rombouts et al., 2000) and PFC hypometabolism in the prefrontal cortex (PFC) (Schroeter et al., 2012) were reported in AD patients. Data from AD postmortem brains indicate that, whereas excitatory pyramidal neurons in the PFC are prone to neurodegeneration (Hof and Morrison, 2004), PFC inhibitory neurons that express the Ca2 + binding protein parvalbumin (PV) are spared (Hof et al., 1991). In transgenic AD model mice, despite substantial neuronal loss in the PFC, no changes in PV-positive and calretinin-positive interneurons were detected (Lemmens et al., 2011). There is substantial loss of cortical spines, the principal site of excitatory synaptic input onto pyramidal neurons, in both the neocortex and hippocampus of AD patients (Cochran et al., 2014). Note, however, that some data do not support decreased excitation in AD. For instance, in the parietal cortex and hippocampus of mice expressing human amyloid precursor protein, nonconvulsive seizure activity resulting from an aberrant increase in network excitability was detected (Palop et al., 2007), and increased excitability of hippocampal CA1 pyramidal neurons was detected in APP/PS1 AD model mice (Siskova et al., 2014).
In this study we explore the hypothesis that memantine can shift the E/I balance in cortical circuitry away from inhibition (Johnson and Kotermanski, 2006) by preferentially reducing NMDAR-mediated excitation of inhibitory neurons. This hypothesis is based on two observations: (1) in physiological Mg2 +, memantine at therapeutic concentrations preferentially inhibits NMDARs that contain the GluN2C or GluN2D subunits (Kotermanski and Johnson, 2009); (2) in adult cortex and hippocampus, the GluN2D subunit is preferentially expressed in inhibitory neurons (Monyer et al., 1994, Standaert et al., 1996). If this hypothesis is correct, then memantine at a concentration that preferentially inhibits GluN2C and GluN2D-containing NMDARs should be more effective at reducing the action potential frequency of inhibitory neurons than of excitatory neurons. To test this prediction we explored in mouse PFC the effects of 10 μM memantine on inhibitory and excitatory synaptic inputs to pyramidal neurons, on NMDAR-mediated synaptic inputs to PV-positive interneurons, and on synaptically-activated action potentials in pyramidal neurons and PV-positive interneurons.
Section snippets
Materials and methods
Experiments were performed on PFC slices from 3 to 7 month old CB6-Tg(Gad1-EGFP)G42jh/J mice of either sex, which express enhanced green fluorescent protein (EGFP) in PV-positive interneurons (http://jaxmice.jax.org/strain/007677.html). All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, and approved by our Institutional Animal Care and Use Committee. Mice were deeply anesthetized with chloral hydrate and decapitated. The brain was
Memantine reduces inhibition of pyramidal neurons
First we assessed memantine's effects on inhibitory input to pyramidal neurons, the cell type that is the main source of excitation in PFC circuitry. All pyramidal neurons studied exhibited typical physiological phenotype including large action potential amplitude, strong adaptation (Fig. 1A, left), and typical morphology (triangular cell body, pronounced apical dendrite, etc.; Fig. 1A, right). To isolate sIPSCs, pyramidal neurons were held at + 12 mV (Cossart et al., 2001), a voltage far from
Discussion
In this study we unveiled a mechanism of action of memantine associated with a change in the E/I balance in PFC circuitry. By measuring excitatory and inhibitory synaptic currents in PFC pyramidal neurons, we found that memantine shifts the E/I balance away from inhibition. The effects of memantine on the NMDAR-mediated synaptic responses and synaptically evoked spiking of PV-positive inhibitory neurons are consistent with memantine's disinhibitory effects. The hypothesized mechanism by which
Acknowledgments
The authors declare no competing financial interests. This work was supported by National Institutes of Health Grants R01MH045817 and R41AG048723, and by Alzheimer's Association Grant NIRG-10-174367. The authors thank Christy Smolak and Lihua Ming for excellent technical assistance, and Nathan Glasgow, Madeleine Wilcox, and Guillermo Gonzalez-Burgos for helpful comments on the manuscript.
References (35)
- et al.
The dendritic hypothesis for Alzheimer's disease pathophysiology
Brain Res. Bull.
(2014) - et al.
Pathway-specific feedforward circuits between thalamus and neocortex revealed by selective optical stimulation of axons
Neuron
(2010) - et al.
Rapid neocortical dynamics: cellular and network mechanisms
Neuron
(2009) - et al.
The aging brain: morphomolecular senescence of cortical circuits
Trends Neurosci.
(2004) - et al.
Mechanism of action of memantine
Curr. Opin. Pharmacol.
(2006) - et al.
Recent insights into the mode of action of memantine and ketamine
Curr. Opin. Pharmacol.
(2015) - et al.
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
Neuron
(1994) - et al.
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease
Neuron
(2007) - et al.
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse
Neuropharmacology
(2007) On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease
Med. Hypotheses
(2005)